RCS - Moderna Inc - Moderna Plans to Bring mRNA Innovation to UK

ModernaAnnouncement

22/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220622:nRSV7177Pa&default-theme=true

RNS Number : 7177P  Moderna Inc  22 June 2022

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

Manufacturing facility would provide access to domestically manufactured
vaccines against respiratory viruses

Moderna would expand its presence in the UK through investments in R&D
activities and capabilities

Collaboration would support the UK with direct access to rapid pandemic
response capabilities

CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.modernatx.com%2F&esheet=52472324&newsitemid=20210805005476&lan=en-US&anchor=Moderna%2C+Inc&index=1&md5=2d3ba9963ffd418d3bd00931ad11b64b)
. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA)
therapeutics and vaccines, today announced an agreement in principle with the
United Kingdom government to establish an mRNA Innovation and Technology
Center in the UK. This state-of-the-art mRNA vaccine manufacturing facility is
expected to provide access to rapid pandemic response capabilities and
Moderna's respiratory virus vaccine candidates. Additionally, Moderna plans to
expand its presence in the UK through investments in research and development
(R&D) activities.

"We are excited to be able to continue our collaboration with the UK
government and Vaccine Taskforce with this new mRNA Innovation and Technology
Center in the UK. The UK has established a world-class life sciences and
research community," said Stéphane Bancel, Chief Executive Officer of
Moderna. "We are committed to global public health, and as we continue to
expand internationally, we are pleased to bring local mRNA manufacturing to
the UK. We look forward to establishing our R&D activities and
capabilities in the country."

Moderna is committed to working with governments, health care professionals,
and other key stakeholders to meet the challenges of the COVID-19 pandemic and
future pathogens. Moderna expects its state-of-the-art manufacturing facility
to produce mRNA vaccines, including vaccines against COVID-19, seasonal
influenza, respiratory syncytial virus (RSV), and potential other vaccines,
with the collaboration of the United Kingdom government.

The facility is intended to also be activated on an urgent basis to support
the UK with direct access to rapid pandemic response capabilities and will
support the UK in its global efforts as part of its "100 Days Mission" to
reduce the impact of future pandemics.

The Company plans to expand its presence in the UK through investments in
R&D to complement its substantial global R&D activities. Moderna is
collaborating with the National Institute for Health Research (NIHR) on a
Phase 3 study investigating Moderna's bivalent Omicron-containing booster
candidate (mRNA-1273.214) in the UK.

Separately, the UK government purchased (https://pr.report/8b6FfQKG) 60
million doses of Moderna's COVID-19 vaccine, which may include authorized
booster vaccine candidates for delivery in 2022 and 2023.

About Moderna

In 10 years since its inception, Moderna has transformed from a research-stage
company advancing programs in the field of messenger RNA (mRNA), to an
enterprise with a diverse clinical portfolio of vaccines and therapeutics
across seven modalities, a broad intellectual property portfolio in areas
including mRNA and lipid nanoparticle formulation, and an integrated
manufacturing plant that allows for both clinical and commercial production at
scale. Moderna maintains alliances with a broad range of domestic and overseas
government and commercial collaborators. Most recently, Moderna's capabilities
have come together to allow the authorized use and approval of one of the
earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied
mRNA science, delivery technology and manufacturing, and has allowed the
development of therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune
diseases. Moderna has been named a top biopharmaceutical employer by Science
for the past seven years. To learn more, visit www.modernatx.com
(https://pr.report/5-3lvMrN) .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
regarding the Company's collaboration with the United Kingdom government to
develop mRNA manufacturing facilities in the UK; the finalization of the
agreement with the government of the UK; the types of medicines to be
manufactured at the facility and pandemic response capabilities; plans to
establish research and development capabilities in the UK; and contracts for
future sales of Moderna's COVID-19 vaccine to the UK government. The
forward-looking statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these forward-looking
statements because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna's control and which could
cause actual results to differ materially from those expressed or implied by
these forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under the
heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K
filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the SEC's website
at www.sec.gov. Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking statements
contained in this press release in the event of new information, future
developments, or otherwise. These forward-looking statements are based on
Moderna's current expectations and speak only as of the date hereof.

Moderna Contacts

Media:

Luke Mircea Willats

Director, Corporate Communications

luke.mirceawillats@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXFLLLLQLBBBB